title: Effects of monocarboxylate transporter inhibition on the oral toxicokinetics/toxicodynamics of γ-hydroxybutyrate and γ-butyrolactone.
abstract: Respiratory depression and death secondary to respiratory arrest have occurred after oral overdoses of γ-hydroxybutyrate (GHB) and its precursor γ-butyrolactone (GBL). GHB is a substrate for monocarboxylate transporters (MCTs), and increasing GHB renal clearance or decreasing GHB absorption via MCT inhibition represents a potential treatment strategy for GHB/GBL overdose. In these studies, GHB and GBL were administered in doses of 1.92, 5.77, and 14.4 mmol/kg orally with and without MCT inhibition to determine effects of this treatment strategy on the oral toxicokinetics and toxicodynamics of GHB and GBL. The competitive MCT inhibitor l-lactate was administered by intravenous infusion starting 1 hour after GHB and GBL administration. Oral administration of l-lactate and the MCT inhibitor luteolin was also evaluated. Respiratory depression was measured using plethysmography. Intravenous l-lactate, but not oral treatments, significantly increased GHB renal and/or oral clearances. At the low dose of GHB and GBL, i.v. l-lactate increased GHB renal clearance. Due to the increased contribution of renal clearance to total clearance at the moderate dose, increased renal clearance translated to an increase in oral clearance. At the highest GHB dose, oral clearance was increased without a significant change in renal clearance. The lack of effect of i.v. l-lactate on renal clearance after a high oral GHB dose suggests possible effects of i.v. l-lactate on MCT-mediated absorption. The resulting increases in oral clearance improved respiratory depression. Intravenous l-lactate also reduced mortality with the high GBL dose. These data indicate i.v. l-lactate represents a potential treatment strategy in oral overdose of GHB and GBL.
authors: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York 14214, USA.
authors: Bridget L
authors: BL
authors: Morse
authors: Marilyn E
authors: ME
authors: Morris
mesh_terms: D015107:4-Butyrolactone / Q000493:pharmacokinetics / Q000633:toxicity; D000042:Absorption; D000284:Administration, Oral; D000818:Animals; D004305:Dose-Response Relationship, Drug; D062787:Drug Overdose / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D019344:Lactic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008657:Metabolic Clearance Rate; D027501:Monocarboxylic Acid Transporters / Q000037:antagonists & inhibitors*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012131:Respiratory Insufficiency / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D012978:Sodium Oxybate / Q000493:pharmacokinetics / Q000633:toxicity
chemical_list: D027501:Monocarboxylic Acid Transporters; D019344:Lactic Acid; D012978:Sodium Oxybate; D015107:4-Butyrolactone
references: Exp Physiol. 2009 Apr;94(4):422-33
references: 19168540
references: Drug Test Anal. 2011 Jul-Aug;3(7-8):417-25
references: 21548140
references: Eur J Pharmacol. 2001 Oct 12;428(3):315-21
references: 11689189
references: Int J Legal Med. 2010 Jan;124(1):1-6
references: 19048269
references: Neurochem Res. 1991 Sep;16(9):965-74
references: 1784339
references: Eur J Pharm Sci. 2012 Dec 18;47(5):801-3
references: 23017433
references: J Pharmacol Exp Ther. 1979 Jan;208(1):7-11
references: 759616
references: Drug Metab Dispos. 2008 Nov;36(11):2244-51
references: 18719239
references: J Anal Toxicol. 2005 Sep;29(6):582-5
references: 16168184
references: AAPS J. 2008;10(1):193-9
references: 18446519
references: Science. 1964 Aug 7;145(3632):583-4
references: 14163782
references: Histol Histopathol. 2009 Feb;24(2):243-64
references: 19085840
references: Pharm Res. 2013 May;30(5):1338-48
references: 23319173
references: J Pharmacol Exp Ther. 2004 Oct;311(1):92-8
references: 15173314
references: Drug Metab Dispos. 2010 Mar;38(3):441-7
references: 19952290
references: Biomed Chromatogr. 2010 Aug;24(8):826-32
references: 20120040
references: Drug Metab Dispos. 2007 Feb;35(2):201-8
references: 17108059
references: J Anal Toxicol. 2004 Nov-Dec;28(8):625-30
references: 15538955
references: J Pharmacol Exp Ther. 2005 Jun;313(3):1194-202
references: 15722403
references: AAPS J. 2010 Sep;12(3):407-16
references: 20461486
references: Ann Emerg Med. 2005 Jun;45(6):614-9
references: 15940094
references: J Pharmacol Exp Ther. 2006 Aug;318(2):751-61
references: 16707723
references: J Anal Toxicol. 2005 Jul-Aug;29(5):398-400
references: 16105269
references: Drug Metab Dispos. 2007 Aug;35(8):1393-9
references: 17502341
references: AAPS J. 2008;10(1):47-55
references: 18446505
references: J Clin Toxicol. 2011 Nov 10;1(2):1000105
references: 24772380
references: Psychopharmacology (Berl). 2009 Jun;204(3):465-76
references: 19198808
references: Eur J Clin Pharmacol. 1993;45(4):353-6
references: 8299669
references: Res Commun Chem Pathol Pharmacol. 1978 Oct;22(1):107-18
references: 725311
references: Res Commun Chem Pathol Pharmacol. 1976 Mar;13(3):425-37
references: 935634
references: Ann Emerg Med. 2006 Feb;47(2):177-83
references: 16431231
references: Drug Metab Dispos. 2009 Jul;37(7):1404-10
references: 19389857
references: Mol Pharmacol. 2012 Aug;82(2):226-35
references: 22561075